Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Supplies
- Symbol: NYSE:HAE
- CUSIP: 40502410
- Web: www.haemonetics.com
Capitalization:- Market Cap: $2.22262 billion
- Outstanding Shares: 52,606,000
Average Prices:- 50 Day Moving Avg: $42.17
- 200 Day Moving Avg: $40.91
- 52 Week Range: $32.76 - $43.77
P/E:- Trailing P/E Ratio: 544.55
- Foreward P/E Ratio: 23.29
- P/E Growth: 3.19
Sales & Book Value:- Annual Revenue: $887.11 million
- Price / Sales: 2.49
- Book Value: $14.71 per share
- Price / Book: 2.85
Profitability:- EBIDTA: $164.54 million
- Net Margins: 0.48%
- Return on Equity: 11.07%
- Return on Assets: 6.54%
Debt:- Debt-to-Equity Ratio: 0.31%
- Current Ratio: 2.57%
- Quick Ratio: 1.72%
Misc:- Average Volume: 321,008 shs.
- Beta: 0.89
- Short Ratio: 9.35
Frequently Asked Questions for Haemonetics Corporation (NYSE:HAE)
What is Haemonetics Corporation's stock symbol?
Haemonetics Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How were Haemonetics Corporation's earnings last quarter?
Haemonetics Corporation (NYSE:HAE) released its quarterly earnings data on Monday, August, 7th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.31 by $0.02. The company earned $211 million during the quarter, compared to the consensus estimate of $211.29 million. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. Haemonetics Corporation's revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the company earned $0.25 EPS. View Haemonetics Corporation's Earnings History.
When will Haemonetics Corporation make its next earnings announcement?
Where is Haemonetics Corporation's stock going? Where will Haemonetics Corporation's stock price be in 2017?
7 brokerages have issued 1 year price targets for Haemonetics Corporation's stock. Their predictions range from $24.00 to $50.00. On average, they anticipate Haemonetics Corporation's stock price to reach $39.83 in the next twelve months. View Analyst Ratings for Haemonetics Corporation.
Who are some of Haemonetics Corporation's key competitors?
Some companies that are related to Haemonetics Corporation include VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), NuVasive (NUVA), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR), Asante Solutions (PUMP), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), Intersect ENT (XENT), Orthofix International N.V. (OFIX) and CryoLife (CRY).
Who are Haemonetics Corporation's key executives?
Haemonetics Corporation's management team includes the folowing people:
- Christopher Simon, President, Chief Executive Officer, Director
- William P. Burke, Chief Financial Officer, Executive Vice President
- Michelle Basil, Executive Vice President, General Counsel
- Neil Ryding, Executive Vice President, Global Operations
- Richard J. Meelia, Non-Executive Independent Chairman of the Board
- Catherine M. Burzik, Independent Director
- Charles J. Dockendorff, Independent Director
- Susan Bartlett Foote, Independent Director
- Ronald G. Gelbman, Independent Director
Who owns Haemonetics Corporation stock?
Haemonetics Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.92%), Vanguard Group Inc. (9.03%), Wells Fargo & Company MN (5.31%), Victory Capital Management Inc. (3.87%), Neuberger Berman Group LLC (3.55%) and HealthCor Management L.P. (3.53%). Company insiders that own Haemonetics Corporation stock include Byron Selman, Christopher J Lindop, Christopher Simon, Ronald G Gelbman, Ronald Merriman, Sandra Jesse and Susan M Hanlon. View Institutional Ownership Trends for Haemonetics Corporation.
Who sold Haemonetics Corporation stock? Who is selling Haemonetics Corporation stock?
Haemonetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Parametric Portfolio Associates LLC, Neuberger Berman Group LLC, Thrivent Financial For Lutherans, American Capital Management Inc., BTIM Corp., Goldman Sachs Group Inc. and Heartland Advisors Inc.. Company insiders that have sold Haemonetics Corporation stock in the last year include Ronald G Gelbman and Ronald Merriman. View Insider Buying and Selling for Haemonetics Corporation.
Who bought Haemonetics Corporation stock? Who is buying Haemonetics Corporation stock?
Haemonetics Corporation's stock was bought by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Wells Fargo & Company MN, Anchor Capital Advisors LLC, Arrowstreet Capital Limited Partnership, Ameriprise Financial Inc., Renaissance Technologies LLC, Balyasny Asset Management LLC and Van Berkom & Associates Inc.. View Insider Buying and Selling for Haemonetics Corporation.
How do I buy Haemonetics Corporation stock?
Shares of Haemonetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics Corporation's stock price today?
One share of Haemonetics Corporation stock can currently be purchased for approximately $41.93.
MarketBeat Community Rating for Haemonetics Corporation (NYSE HAE)MarketBeat's community ratings are surveys of what our community members think about Haemonetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Haemonetics Corporation (NYSE:HAE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 3 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.29) |
| Consensus Price Target: | $39.83 (5.00% downside) |
Analysts' Ratings History for Haemonetics Corporation (NYSE:HAE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/8/2017 | Barrington Research | Upgrade | Market Perform -> Outperform | $48.00 | High |  |
| 7/27/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $48.00 | High | |
| 7/13/2017 | JMP Securities | Upgrade | Market Perform -> Outperform | $50.00 | High | |
| 11/7/2016 | BTIG Research | Reiterated Rating | Neutral | | N/A | |
| 11/7/2016 | Benchmark Co. | Boost Price Target | Hold | $32.00 -> $34.00 | N/A | |
| 10/14/2016 | Off Wall Street | Initiated Coverage | Sell | $24.00 | N/A | |
| 9/20/2016 | CJS Securities | Downgrade | Market Outperform -> Market Perform | $35.00 | N/A | |
| 8/15/2016 | Sidoti | Downgrade | Buy -> Neutral | $39.00 | N/A | |
| 5/16/2016 | Goldman Sachs Group, Inc. (The) | Upgrade | Sell -> Neutral | $29.00 | N/A | |
| 5/12/2016 | Morgan Stanley | Reiterated Rating | Hold | | N/A | |
| 2/2/2016 | William Blair | Reiterated Rating | Market Perform | | N/A | |
| 11/23/2015 | Raymond James Financial, Inc. | Downgrade | Market Perform -> Underperform | | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Haemonetics Corporation (NYSE:HAE)Earnings History by Quarter for Haemonetics Corporation (NYSE HAE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | | | | | | | |
| 8/7/2017 | Q1 2018 | $0.31 | $0.33 | $211.29 million | $211.00 million | View | Listen | |
| 5/8/2017 | Q4 2017 | $0.37 | $0.39 | $215.06 million | $228.10 million | View | Listen | |
| 2/6/2017 | Q317 | $0.40 | $0.43 | $220.00 million | $227.80 million | View | Listen | |
| 11/7/2016 | Q217 | $0.35 | $0.46 | $210.72 million | $220.30 million | View | Listen | |
| 8/1/2016 | Q117 | $0.28 | $0.25 | $205.41 million | $210.00 million | View | Listen | |
| 5/2/2016 | Q416 | $0.46 | $0.37 | $245.08 million | $243.20 million | View | Listen | |
| 2/1/2016 | Q316 | $0.46 | $0.48 | $237.37 million | $233.40 million | View | Listen | |
| 11/4/2015 | Q216 | $0.40 | $0.44 | $226.50 million | $219.70 million | View | Listen | |
| 7/27/2015 | Q116 | $0.33 | $0.35 | $215.62 million | $213.40 million | View | Listen | |
| 4/27/2015 | Q415 | $0.51 | $0.47 | $239.20 million | $226.50 million | View | Listen | |
| 1/29/2015 | Q315 | $0.51 | $0.53 | $235.45 million | $231.80 million | View | Listen | |
| 11/3/2014 | Q215 | $0.45 | $0.47 | $229.90 million | $227.60 million | View | Listen | |
| 7/30/2014 | Q115 | $0.35 | $0.38 | $215.85 million | $224.49 million | View | Listen | |
| 4/28/2014 | Q414 | $0.58 | $0.46 | $244.87 million | $241.00 million | View | Listen | |
| 1/27/2014 | Q314 | $0.61 | $0.61 | $243.71 million | $242.10 million | View | Listen | |
| 10/28/2013 | Q214 | $0.57 | $0.66 | $239.51 million | $235.80 million | View | Listen | |
| 7/29/2013 | Q1 2014 | $0.47 | $0.46 | $232.98 million | $219.50 million | View | Listen | |
| 5/1/2013 | Q4 2013 | $0.46 | $0.48 | $249.33 million | $249.90 million | View | Listen | |
| 1/30/2013 | Q3 2013 | $0.47 | $0.50 | $251.93 million | $247.40 million | View | Listen | |
| 10/29/2012 | Q213 | $0.77 | $0.90 | $223.47 million | $218.18 million | View | N/A | |
| 8/1/2012 | | $0.71 | $0.55 | | | View | N/A | |
| 4/30/2012 | | $0.83 | $0.80 | | | View | N/A | |
| 1/30/2012 | | $0.80 | $0.86 | | | View | N/A | |
| 10/31/2011 | | $0.77 | $0.72 | | | View | N/A | |
| 8/1/2011 | | $0.77 | $0.65 | | | View | N/A | |
| 5/2/2011 | | $0.83 | $0.85 | | | View | N/A | |
| 1/31/2011 | | $0.82 | $0.89 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Haemonetics Corporation (NYSE:HAE)2017 EPS Consensus Estimate: $1.35
2018 EPS Consensus Estimate: $1.59
2019 EPS Consensus Estimate: $1.59
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.26 | $0.30 | $0.27 |
| Q2 2017 | 3 | $0.29 | $0.34 | $0.32 |
| Q3 2017 | 3 | $0.37 | $0.42 | $0.39 |
| Q4 2017 | 3 | $0.35 | $0.38 | $0.36 |
| Q1 2018 | 3 | $0.25 | $0.37 | $0.30 |
| Q2 2018 | 3 | $0.38 | $0.47 | $0.44 |
| Q3 2018 | 3 | $0.43 | $0.47 | $0.45 |
| Q4 2018 | 2 | $0.41 | $0.41 | $0.41 |
| Q1 2019 | 1 | $0.25 | $0.25 | $0.25 |
| Q2 2019 | 1 | $0.45 | $0.45 | $0.45 |
| Q3 2019 | 1 | $0.47 | $0.47 | $0.47 |
| Q4 2019 | 1 | $0.42 | $0.42 | $0.42 |
(Data provided by Zacks Investment Research)
Dividend History for Haemonetics Corporation (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Haemonetics Corporation (NYSE:HAE)Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for Haemonetics Corporation (NYSE:HAE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/22/2017 | Ronald Merriman | Director | Sell | 17,471 | $40.33 | $704,605.43 | |
| 12/12/2016 | Ronald G Gelbman | Director | Sell | 5,683 | $40.30 | $229,024.90 | |
| 8/17/2016 | Ronald Merriman | Director | Sell | 4,337 | $35.14 | $152,402.18 | |
| 8/4/2016 | Christopher Simon | CEO | Buy | 60,000 | $35.00 | $2,100,000.00 | |
| 10/26/2015 | Byron Selman | Insider | Sell | 344 | $32.13 | $11,052.72 | |
| 10/26/2015 | Christopher J Lindop | CFO | Sell | 436 | $32.13 | $14,008.68 | |
| 10/26/2015 | Sandra Jesse | EVP | Sell | 778 | $32.13 | $24,997.14 | |
| 10/26/2015 | Susan M Hanlon | VP | Sell | 497 | $32.13 | $15,968.61 | |
| 9/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $35.15 | $230,900.35 | |
| 9/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $35.63 | $169,776.95 | |
| 8/20/2015 | Christopher J. Lindop | CFO | Sell | 4,902 | $38.49 | $188,677.98 | |
| 8/17/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.28 | $258,030.32 | |
| 7/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $39.09 | $191,619.18 | |
| 7/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.59 | $260,066.71 | |
| 7/6/2015 | Peter M Allen | Insider | Sell | 30,494 | $40.19 | $1,225,553.86 | |
| 7/2/2015 | Jonathan White | Insider | Sell | 2,385 | $41.14 | $98,118.90 | |
| 6/22/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $42.51 | $208,384.02 | |
| 6/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $42.51 | $279,248.19 | |
| 6/10/2015 | Susan M Hanlon | VP | Sell | 6,000 | $43.00 | $258,000.00 | |
| 6/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $41.39 | $197,223.35 | |
| 5/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.65 | $204,168.30 | |
| 5/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $40.74 | $194,126.10 | |
| 4/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.55 | $203,678.10 | |
| 4/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.51 | $212,090.15 | |
| 3/27/2015 | Susan M Hanlon | VP | Sell | 7,000 | $43.46 | $304,220.00 | |
| 3/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $44.26 | $216,962.52 | |
| 3/10/2015 | Susan Bartlett Foote | Director | Sell | 11,328 | $43.84 | $496,619.52 | |
| 3/5/2015 | Ronald G Gelbman | Director | Sell | 7,707 | $44.76 | $344,965.32 | |
| 3/4/2015 | Ronald Merriman | Director | Sell | 14,258 | $43.80 | $624,500.40 | |
| 3/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.41 | $211,613.65 | |
| 2/18/2015 | Pedro P Granadillo | Director | Sell | 11,328 | $43.45 | $492,201.60 | |
| 2/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $39.15 | $186,549.75 | |
| 1/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $37.20 | $177,258.00 | |
| 12/1/2014 | Brian Concannon | CEO | Sell | 4,765 | $36.72 | $174,970.80 | |
| 11/3/2014 | Brian Concannon | CEO | Sell | 4,765 | $35.86 | $170,872.90 | |
| 10/13/2014 | Peter M Allen | Insider | Sell | 36,426 | $35.22 | $1,282,923.72 | |
| 8/12/2014 | Ronald Merriman | Director | Sell | 13,602 | $35.76 | $486,407.52 | |
| 8/1/2014 | Brian Concannon | CEO | Sell | 4,380 | $35.27 | $154,482.60 | |
| 7/7/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $35.97 | $209,956.89 | |
| 6/12/2014 | Ronald G Gelbman | Director | Sell | 9,184 | $34.00 | $312,256.00 | |
| 6/6/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $34.69 | $202,485.53 | |
| 5/12/2014 | Susan Bartlett Foote | Director | Sell | 9,184 | $33.16 | $304,541.44 | |
| 5/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.14 | $181,764.18 | |
| 5/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $30.01 | $138,046.00 | |
| 4/28/2014 | Peter Allen | Insider | Sell | 30,000 | $30.70 | $921,000.00 | |
| 4/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.98 | $186,667.26 | |
| 4/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $32.71 | $150,466.00 | |
| 3/6/2014 | Ronald Gelbman | Director | Sell | 12,000 | $36.17 | $434,040.00 | |
| 3/3/2014 | Brian Concannon | CEO | Sell | 4,600 | $36.36 | $167,256.00 | |
| 2/18/2014 | Susan Hanlon | VP | Sell | 3,690 | $39.00 | $143,910.00 | |
| 2/7/2014 | Jonathan White | Insider | Sell | 1,880 | $38.66 | $72,680.80 | |
| 2/3/2014 | Brian Concannon | CEO | Sell | 7,600 | $37.63 | $285,988.00 | |
| 1/27/2014 | Susan Hanlon | VP | Sell | 3,206 | $38.37 | $123,014.22 | |
| 1/10/2014 | Susan Hanlon | VP | Sell | 4,000 | $41.80 | $167,200.00 | |
| 1/2/2014 | Brian Concannon | CEO | Sell | 7,600 | $41.58 | $316,008.00 | |
| 12/16/2013 | Susan Hanlon | VP | Sell | 4,000 | $43.50 | $174,000.00 | |
| 12/9/2013 | Susan Hanlon | VP | Sell | 3,138 | $43.07 | $135,153.66 | |
| 12/2/2013 | Brian Concannon | CEO | Sell | 7,600 | $42.31 | $321,556.00 | |
| 11/12/2013 | Michael Kelly | Insider | Sell | 61,400 | $39.70 | $2,437,580.00 | |
| 11/1/2013 | Brian Concannon | CEO | Sell | 7,600 | $39.96 | $303,696.00 | |
| 10/14/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.41 | $56,574.00 | |
| 9/13/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.36 | $56,504.00 | |
| 9/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $39.87 | $518,310.00 | |
| 8/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $42.24 | $549,120.00 | |
| 7/12/2013 | Michael P Kelly | Insider | Sell | 1,400 | $44.10 | $61,740.00 | |
| 7/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.87 | $544,310.00 | |
| 6/18/2013 | Christopher J Lindop | CFO | Sell | 68,628 | $42.50 | $2,916,690.00 | |
| 6/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $42.17 | $59,038.00 | |
| 6/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.15 | $534,950.00 | |
| 5/21/2013 | Christopher J Lindop | CFO | Sell | 42,882 | $42.00 | $1,801,044.00 | |
| 5/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $39.66 | $55,524.00 | |
| 5/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $38.66 | $502,580.00 | |
| 12/3/2012 | Brian Concannon | CEO | Sell | 13,000 | $40.75 | $529,750.00 | |
| 11/12/2012 | Pedro P Granadillo | Director | Sell | 16,000 | $80.40 | $1,286,400.00 | |
| 9/4/2012 | Brian Concannon | CEO | Sell | 6,500 | $73.68 | $478,920.00 | |
| 9/4/2012 | Christopher J Lindop | CFO | Sell | 61,783 | $74.34 | $4,592,948.22 | |
(Data available from 1/1/2013 forward)
Headline Trends for Haemonetics Corporation (NYSE:HAE)
Latest Headlines for Haemonetics Corporation (NYSE:HAE)
| Source: |
|
| Date | Headline |
|---|
 | Haemonetics Appoints David J. Wilson Plasma Business Unit President
finance.yahoo.com - September 14 at 7:59 PM |
 | Haemonetics Corporation (HAE) Expected to Post Quarterly Sales of $219.67 Million
www.americanbankingnews.com - September 11 at 10:00 AM |
| Analysts Anticipate Haemonetics Corporation (HAE) Will Post Earnings of $0.42 Per Share
www.americanbankingnews.com - September 9 at 10:42 AM |
 | Frank Magliochetti - Highlights the Potential of Wearable Sensors in Healthcare Diagnosis
www.finanznachrichten.de - August 31 at 5:15 AM |
| Haemonetics Corporation (HAE) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - August 30 at 12:44 AM |
| Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
finance.yahoo.com - August 29 at 7:51 PM |
| Haemonetics Corporation (HAE) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 29 at 5:52 PM |
| Jefferies Group Research Analysts Reduce Earnings Estimates for Haemonetics Corporation (HAE)
www.americanbankingnews.com - August 28 at 11:22 AM |
| Haemonetics Corporation (HAE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 24 at 1:38 PM |
| Haemonetics Corporation (HAE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 23 at 3:28 PM |
| Zacks: Brokerages Anticipate Haemonetics Corporation (HAE) to Post $0.42 EPS
www.americanbankingnews.com - August 21 at 10:20 PM |
| Haemonetics Corporation (HAE) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 16 at 3:48 PM |
| See what the IHS Markit Score report has to say about Haemonetics Corp.
finance.yahoo.com - August 11 at 1:34 AM |
| Research Analysts Set Expectations for Haemonetics Corporation's Q3 2018 Earnings (NYSE:HAE)
www.americanbankingnews.com - August 10 at 12:38 PM |
| Haemonetics Corporation (HAE) Rating Increased to B- at TheStreet
www.americanbankingnews.com - August 9 at 9:10 AM |
| Haemonetics Corporation (HAE) Upgraded to "Outperform" by Barrington Research
www.americanbankingnews.com - August 8 at 8:30 AM |
| Edited Transcript of HAE earnings conference call or presentation 7-Aug-17 12:00pm GMT
finance.yahoo.com - August 8 at 1:47 AM |
 | Haemonetics Posts Profit In Q1, Above Market; Revenues Miss Estimates
www.rttnews.com - August 7 at 3:43 PM |
 | Haemonetics (HAE) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 3:43 PM |
 | BRIEF-Haemonetics Corp reports Q1 earnings per share $0.38
www.reuters.com - August 7 at 3:42 PM |
| Haemonetics 1st Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - August 7 at 3:42 PM |
| Haemonetics tops 1Q profit forecasts
finance.yahoo.com - August 7 at 3:42 PM |
| Haemonetics Corporation (HAE) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 7 at 8:50 AM |
| Zacks: Brokerages Anticipate Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $213.55 Million
www.americanbankingnews.com - August 5 at 7:08 AM |
| Haemonetics Corporation (NYSE:HAE) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 5 at 12:40 AM |
| Haemonetics Corp. – Value Analysis (NYSE:HAE) : August 5, 2017
finance.yahoo.com - August 5 at 12:38 AM |
| Why Earnings Season Could Be Great for Haemonetics (HAE)
finance.yahoo.com - August 3 at 7:21 PM |
| Haemonetics Corporation (HAE) Expected to Post Earnings of $0.31 Per Share
www.americanbankingnews.com - August 3 at 6:10 PM |
| Haemonetics Corporation (HAE) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 7:54 AM |
 | Haemonetics Announces FDA Clearance of New Plasmapheresis System Branded ...
www.prnewswire.com - July 29 at 3:05 AM |
| Haemonetics Announces FDA Clearance of New Plasmapheresis System Branded NexSys PCS™
finance.yahoo.com - July 28 at 10:04 PM |
| Jefferies Group LLC Reiterates "Buy" Rating for Haemonetics Corporation (NYSE:HAE)
www.americanbankingnews.com - July 27 at 6:52 PM |
| Reviewing Haemonetics Corporation (NYSE:HAE) and DENTSPLY SIRONA (XRAY)
www.americanbankingnews.com - July 25 at 10:19 PM |
| Haemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : July 24, 2017
finance.yahoo.com - July 24 at 10:00 PM |
| Haemonetics Sets Date for Publishing 1st Quarter Fiscal 2018 Results: August 7, 2017
finance.yahoo.com - July 18 at 9:17 PM |
| Haemonetics Corporation (HAE) Rating Increased to Outperform at JMP Securities
www.americanbankingnews.com - July 16 at 7:02 PM |
| Haemonetics Corporation (NYSE:HAE) Expected to Post Quarterly Sales of $213.55 Million
www.americanbankingnews.com - July 14 at 2:06 PM |
| Believe In The Haemonetics Turnaround Story; JMP Upgrades To Market Outperform
finance.yahoo.com - July 13 at 8:59 PM |
| Haemonetics Co. (HAE) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM |
| Brokerages Anticipate Haemonetics Corporation (HAE) to Announce $0.31 Earnings Per Share
www.americanbankingnews.com - July 12 at 12:56 PM |
| Haemonetics Corporation (HAE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 11 at 12:40 AM |
| ETFs with exposure to Haemonetics Corp. : July 6, 2017
finance.yahoo.com - July 7 at 5:58 AM |
| Haemonetics Corporation (HAE) Lowered to Sell at BidaskClub
www.americanbankingnews.com - June 23 at 9:00 PM |
| Haemonetics Announces Formation of Scientific Advisory Council
finance.yahoo.com - June 23 at 2:58 AM |
| Brokerages Anticipate Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $213.55 Million
www.americanbankingnews.com - June 18 at 9:42 AM |
| Haemonetics Will Webcast Investor and Analyst Meeting
finance.yahoo.com - June 14 at 7:06 PM |
| Haemonetics Rides on Solid Plasma, Slows Blood Center Growth
finance.yahoo.com - June 14 at 7:06 PM |
| Haemonetics Corp. :HAE-US: Earnings Analysis: Q4, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 11:50 AM |
| Haemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 14 at 12:46 AM |
| ETFs with exposure to Haemonetics Corp. : June 13, 2017
finance.yahoo.com - June 13 at 5:24 PM |
Haemonetics Corporation (HAE) Chart for Wednesday, September, 20, 2017
